serum will soon be released to the marketplace that will have only one analyzed value for each constituent. The laboratorian can utilize the "true value" as assigned by the manufacturer in order to get an overall indication of where the individual laboratory stands with respect to accuracy (and bias) as assigned by the best selected methods for each analyte.
We stifi believe that the Coefficient of Analysis is a validstatistical formula that interrelates precision and accuracy to a single figure of merit, the Coefficient ofAnalysis, which describes theoverall laboratory performance. As stated by Lang and Mueller(Clin. Chem. 27: 1951 -1952 , 1981 , our creatine kinase isoenzyme (CKMB) test methodology indicates that the intended use of our CKMB pack is to quantitatively measure the activity of CKMB in serum. Our practice is to recommend the specific specimens for which our methods are designed and qualified, and for which we anticipate a need.For CKMB, we did not anticipate a need for heparinized plasma as a sample, so we did not comment on its use.
Allan
The reporteddata found duringthe use of this method at St. Mary's Hospital indicate that the primary difference between serum and heparinized plasma is that the results for plasma are, on the average, 13 U/L higher than the serum results. Considering that the aca normal range is 0-8 U/L, this difference alone would make normal heparinized specimens appear diagnostically positive without introducing the uncertainty of presuming that electrophoresis is diagnostic.
We are pleased that Lang and Mueller's findings support our recommendation that heparinized plasma not be used for the determination of CKMB on the aca. To measure TK activity, we, like Bayoumi and Rosalki, use ribose-5-phosphate as substrate and form glyceraldehyde-3-phosphate (reaction 1). Unlike these authors, we stop reaction 1 (first step) by deproteinization with trichloroacetic acid before starting reactions 2 and 3. This second step is used to measure, without interference from hemoglobin, the amount of glyceraldehyde phosphateformed in the first step. As a result of the suppression of the high absorbance of hemoglobin, the rate of NADH oxidation, which provides a measure of TK activity, is recorded in endpointinsteadofwiththe15-mm reaction-rate monitoring previously described (3). First step: To 100 ML of hemolysate, add 100 ML of thiamin pyrophosphate chloride (TPP; Boehringer, Mannheim, F.R.G.), 10 mmolfL in Tris HC1 buffer (100 mmol/L, pH 7.6 at 37 #{176}C). For the assay of activity without TPP, replace it with 100 ML of Tris HC1 buffer. Always measure activities with and without TPP concurrently.
Wendell R. O'Neal
Incubate the mixture at 37 #{176}C for 15 mm to ensure optimalactivation ofTK by TPP. Add 50 ML of disodium ribose-5-phosphate (Boehringer)solution, 110 mmol/L in Tris HC1 bufferkept at 37 #{176}C, and incubate for a further 60 mm at 37 #{176}C. Then add 150 ML of 0,45 mol/L trichloroacetic acid (TCA), centrifuge, and assay the supernate.
Second Ribose-5-P04 + xylulose-5-PO4
TK ± sedoheptulose-7-P04 + glyceraldehyde-3-P04
Second step:
Calculate the TK activity as follows:
1A x (1120 x 400)/(6.23 X 50)
X (1/x) = activity in U/g Hb where is the decrease in absorbance at 340 nm after 1 mm, 6.23 is the millimolar absorptivity of NADH at 340 nm, 1120 is the final volume in microliters, 400/50 is the dilution factor, and x is the hemoglobin concentration in grams per deciliter. The TPP effect is the percentageactivation of TK resulting from the in vitro addition of the coenzyme. The unit of TK is that activity giving rise to 1 Mmol of glyceraldehyde-3-phosphate per gram of hemoglobin
